What Zymvol Biomodeling does

Zymvol Biomodeling S.L. is a Barcelona-based computational biocatalysis company founded in 2017 that provides B2B enzyme discovery and optimization services to enterprise R&D teams in pharmaceuticals, biotechnology, chemicals, cosmetics, and food/flavors. The company's core product is a "Physics-AI hyperrealistic" enzyme modeling platform that combines bioinformatics, molecular modelling, and artificial intelligence to predict enzyme function and engineer optimized variants in silico before wet-lab validation. Disclosed outcomes include 10x activity increases versus patented benchmarks, 99% enantiomeric excess in API production, 40x operational stability gains for industrial enzymes, and 99.5% reductions in lab screening workload across more than 100 delivered projects in 10+ countries.

Zymvol operates a project-based professional services model: enterprise clients engage Zymvol's team directly to scope custom enzyme development campaigns, with pricing not publicly disclosed. The customer base is concentrated among large pharmaceutical and chemical multinationals — including Boehringer Ingelheim, Sanofi, Axplora, Syensqo, Medichem, Olon, and Rubi — with the company reporting 70%+ repeat-customer rates. Distribution is exclusively direct enterprise sales supported by content marketing, peer-reviewed publications, and case-study-driven demand generation. The company holds ISO 9001 and ISO 27001 certifications, supporting procurement processes in regulated industries, and operates a related digital sub-brand, Zymbrain.ai, suggesting movement toward a software/platform layer beyond pure services.

The company is privately held (SL) and has raised cumulative funding of roughly $7.5-8M since 2015, including grants and equity from the EU's EISMEA, IQS Tech Factory, regional investor Avançsa, and venture investors Elaia, Faber, and Übermorgen Ventures. Most recently, Zymvol closed a $3.15M round in February 2025 led by Faber to scale team, laboratory, and production capacity. The company is led by co-founders Maria Lucas (CEO), Emanuele Monza (CSO), and Víctor Gil (CTO), with Mona Costelloe serving as Chief Business Officer.

Name

Zymvol Biomodeling

Legal name

ZYMVOL BIOMODELING, S.L.

Website

http://zymvol.com/

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Zymvol Biomodeling is a Barcelona-based B2B services firm that uses proprietary physics-AI computational modeling to discover and optimize industrial enzymes for enterprise R&D teams in pharmaceuticals, biotechnology, chemicals, cosmetics, and food.

Ownership category

akta.pro rank

Product category

Computational Enzyme Design / Biocatalysis Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Computational enzyme design
• Biocatalysis services
• Molecular modeling enzymes
• Enzyme discovery services
• Enzyme optimization services

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Enzyme Discovery Services: Project-based enzyme discovery and optimization services for pharmaceutical, biotech, chemical, cosmetics, and food industries. The company provides molecular modeling solutions to help companies in early-stage enzyme development, delivering custom-made biocatalysts that provide additional value to clients.
2. Enzyme Optimization Services: In silico enzyme optimization using proven computational technology to lower operational costs and boost productivity for clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Zymvol provides project-based Enzyme Discovery and Enzyme Optimization services that use a proprietary physics-AI hyperrealistic molecular modeling platform to screen sequence spaces and computationally engineer industrial enzymes for pharmaceutical, biotech, chemical, cosmetics, and food-industry customers. Deliverables are custom-made biocatalysts and engineering campaigns that compress wet-lab work, reduce R&D risk, and accelerate biocatalysis implementation.

Product overview

Zymvol Biomodeling offers a service-oriented portfolio centered on enzyme discovery and enzyme optimization. The company uses a physics-AI hyperrealistic approach for molecular modeling to assist companies in the early stages of enzyme development. Their two core offerings—Enzyme Discovery and Enzyme Optimization—work together to help R&D managers identify optimal starting points for enzyme ventures and then refine those enzymes computationally before experimental validation. The company serves diverse industries including pharmaceuticals, biotechnology, chemicals, and cosmetics.

Differentiator

Problem solved

Functional benefit

Brands

• Zymbrain.ai: A platform mentioned in the footer of the Zymvol website, suggesting a related digital product or service offering in the enzyme/bioinformatics space.

Products and services

• Enzyme Discovery AI-powered enzyme identification service that computationally screens up to 1.5 billion sequences to select the most promising enzymes matching specific industrial needs; enables enterprise R&D managers in pharmaceutical, biotech, chemical, cosmetics, and food companies to identify optimal starting points for biocatalysis programs and outpace competition in enzyme selection.
• Enzyme Optimization In silico enzyme engineering service that optimizes existing enzymes using Zymvol's physics-AI hyperrealistic computational platform to lower operational costs and boost productivity, delivering outcomes such as 10x activity increases, 40x operational stability improvements, and high stereoselectivity for pharmaceutical and chemical customers.

Quantifiable outcome

• 10x higher activity than leading patented enzyme with 99% enantiomeric excess in API production
• +4 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Arzeda: Arzeda combines AI-driven protein design with laboratory validation to create novel enzymes and proteins for industrial and consumer applications. Closely comparable to Zymvol's Physics-AI platform, with a similar focus on computational enzyme discovery and optimization for chemicals, materials, and life sciences customers.
• Cradle: Cradle uses generative AI to design and optimize proteins, including enzymes, for biotech and industrial customers. Zymvol and Cradle both sell computational enzyme engineering to enterprise pharma/chem customers, though Cradle is more productized around a SaaS-style platform while Zymvol remains service-led.
• Codexis: Codexis is a long-established enzyme engineering company serving pharmaceutical and industrial customers with both proprietary enzymes and protein engineering services. Zymvol competes head-on in pharma API biocatalysis and custom enzyme optimization, though Codexis operates at significantly larger scale and is publicly listed.
• EnginZyme: EnginZyme develops enzymes and cell-free biocatalysis processes for sustainable chemical manufacturing. Comparable to Zymvol's industrial biocatalysis focus for chemical customers, with similar use cases in pharma intermediates and green chemistry.

Broad incumbents

• Schrödinger: Schrödinger provides physics-based computational chemistry and molecular simulation software widely used in pharma R&D. Zymvol's Physics-AI platform competes with parts of Schrödinger's stack for enzyme modeling and lead identification, but Schrödinger serves a much broader drug discovery market with an established SaaS business.
• Ginkgo Bioworks: Ginkgo Bioworks operates a large-scale synthetic biology platform offering custom organism engineering, including enzyme development for industrial customers. Overlaps with Zymvol on enzyme and biocatalysis programs but operates a much broader and more capital-intensive service offering across pharma, food, and agriculture.

Emerging players

• TeselaGen: TeselaGen offers a synthetic biology platform combining AI with laboratory automation for protein and pathway engineering. Partial overlap with Zymvol's enzyme design workflow, with a stronger emphasis on a software platform and customers in biotech rather than pharma API production.
• Bota Bio: Bota Bio applies AI and computational biology to engineer enzymes and microbes for sustainable biomanufacturing, including pharmaceutical intermediates and consumer products. Direct overlap with Zymvol's industrial enzyme design mission at a similar stage, with comparable use cases in pharma and green chemistry.

Others

• BIOSERV / BioTools Innovator: BioTools Innovator is an accelerator that has supported Zymvol (per the funding record showing a 2022-07 BioTools Innovator round). Functions as an enabling ecosystem participant for life science tools and services startups rather than a direct competitor.
• PROvendis: PROvendis is a European technology transfer and IP commercialization organization associated with pharma and chemistry research. Relevant to Zymvol as a potential channel for IP licensing of discovered enzymes and as an ecosystem participant in European industrial biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zymvol
• Xx.com/zymvol

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zymvol Biomodeling